{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Failure+Chronic",
    "query": {
      "condition": "Kidney Failure Chronic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1710,
    "total_pages": 171,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Failure+Chronic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T22:15:26.361Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00548249",
      "title": "Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End-Stage Renal Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Standard Bicarbonate Solution",
          "type": "DEVICE"
        },
        {
          "name": "Soluble Ferric Pyrophosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Rockwell Medical Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2007-08",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-02",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 27,
      "location_summary": "Tempe, Arizona • Hacienda Heights, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Hacienda Heights",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00548249"
    },
    {
      "nct_id": "NCT01238796",
      "title": "A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Diseases",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2010-12",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01238796"
    },
    {
      "nct_id": "NCT01416896",
      "title": "New Needle for Two-Needle Hemodialysis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Hemodialysis using the standard venous needle",
          "type": "PROCEDURE"
        },
        {
          "name": "Hemodialysis using a new venous needle, the \"BME needle\"",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Biomedical Enterprises Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 70,
      "start_date": "2011-08",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2011-08-15",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416896"
    },
    {
      "nct_id": "NCT00223678",
      "title": "Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2000-06",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223678"
    },
    {
      "nct_id": "NCT01426724",
      "title": "Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Contrast Enhanced Ultrasonography",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-09",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01426724"
    },
    {
      "nct_id": "NCT00982423",
      "title": "The Effects of Decreasing the Lasix Dose on the Cardiorenal System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure",
        "Kidney Dysfunction"
      ],
      "interventions": [
        {
          "name": "Furosemide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 41,
      "start_date": "2009-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-07-20",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00982423"
    },
    {
      "nct_id": "NCT01985360",
      "title": "ISCHEMIA-Chronic Kidney Disease Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Coronary Artery Disease",
        "Heart Diseases",
        "Myocardial Ischemia",
        "Kidney Disease",
        "End Stage Renal Failure on Dialysis"
      ],
      "interventions": [
        {
          "name": "Cardiac Catheterization",
          "type": "PROCEDURE"
        },
        {
          "name": "Coronary Artery Bypass Graft Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Percutaneous Coronary Intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "Lifestyle",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 777,
      "start_date": "2014-01",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01985360"
    },
    {
      "nct_id": "NCT02134314",
      "title": "C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Kidney Failure",
        "Delayed Graft Function",
        "Ischemic Reperfusion Injury"
      ],
      "interventions": [
        {
          "name": "C1 Esterase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-09",
      "completion_date": "2017-03-13",
      "has_results": true,
      "last_update_posted_date": "2018-06-25",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134314"
    },
    {
      "nct_id": "NCT05655325",
      "title": "Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Home-based walking exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attention control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2024-06-18",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05655325"
    },
    {
      "nct_id": "NCT05118074",
      "title": "Nova Max Creatinine and eGFR Meter System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Diseases",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Creatinine, eGFR",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Nova Biomedical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2021-06-08",
      "completion_date": "2024-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-06-10T22:15:26.361Z",
      "location_count": 3,
      "location_summary": "Medley, Florida • Miami Gardens, Florida • Miami Lakes, Florida",
      "locations": [
        {
          "city": "Medley",
          "state": "Florida"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118074"
    }
  ]
}